This is a regulatory intimation regarding an upcoming board meeting of Caplin Point Laboratories Limited.
A meeting of the Board of Directors is scheduled to be held on Thursday, November 12, 2026. The primary agenda of the meeting is to consider and approve the unaudited financial results of the Company for both the quarter and half-year ended September 30, 2026. The results will be reviewed on both a standalone and consolidated basis.
This intimation is being provided in compliance with the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure also confirms that the trading window for dealing in the company's securities by Designated Persons and their immediate relatives remains closed. This closure, which was previously communicated via a letter dated September 28, 2026, is in effect from October 01, 2026, to November 14, 2026 (both days inclusive). This measure is in accordance with the company's Code of Conduct to regulate, monitor, and report trading by insiders, read with the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The letter is signed by Venkatram G, General Counsel & Company Secretary (Membership No: A23989).